share_log

Oppenheimer Initiates Coverage On Kymera Therapeutics With Outperform Rating, Announces Price Target of $53

Moomoo 24/7 ·  Apr 22 07:28

Oppenheimer analyst Jeff Jones initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $53.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment